Brady Todd C 4
4 · Aldeyra Therapeutics, Inc. · Filed Mar 12, 2024
Insider Transaction Report
Form 4
Brady Todd C
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-03-11$3.27/sh−97,914$320,521→ 1,556,622 total - Award
Stock Option (right to buy)
2024-03-09+1,081,201→ 1,081,201 totalExercise: $3.62Exp: 2034-03-08→ Common Stock (1,081,201 underlying) - Sale
Common Stock
2024-03-12$3.05/sh−85,324$260,238→ 1,471,298 total
Footnotes (4)
- [F1]These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.35. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.11. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024.